Lem

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lem

Property Description
Active ingredient Meloxicam
Form Oral dosage forms (Tablets, Capsules, Suspensions); Intravenous Solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Symptomatic relief from pain, swelling, and stiffness
Origin Synthetic compound (Oxicam class)

What Type of Medicine is Lem (Meloxicam)?

Lem is a prescription-only pharmaceutical product whose therapeutic function is provided by its single active ingredient, Meloxicam. The medication belongs to the widely utilized class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Chemically, Meloxicam is a synthetic compound categorized as an enolic acid derivative within the oxicam group, which establishes its core chemical structure. The drug is primarily used as an anti-inflammatory analgesic agent, with its profile tied directly to the established efficacy of Meloxicam in controlling symptomatic discomfort.

What is the Purpose and Composition of Lem?

The primary general purpose of Lem is to offer symptomatic relief by mitigating the pain, swelling, and stiffness associated with chronic or acute inflammatory conditions. The medication is presented in a flexible portfolio of dosage forms, including traditional oral dosage forms (tablets and capsules) and an intravenous solution for specific clinical settings, ensuring suitability for various patient needs. Meloxicam works within the inflammatory process, reducing discomfort. The final product combines the active therapeutic agent Meloxicam with necessary, inert excipients that provide the essential vehicle for drug stability and consistent absorption.

How Does Lem Differ from Other NSAIDs?

Lem differentiates itself through the specific mechanism of its active compound, Meloxicam, which is a preferential Cyclooxygenase-2 (COX-2) inhibitor. This targeted approach suppresses the enzyme primarily responsible for synthesizing the prostaglandins that drive inflammation. While the entire NSAID class provides relief, Meloxicam’s profile offers three distinct physiological benefits: marked anti-inflammatory activity, direct analgesic activity against pain signals, and a complementary antipyretic activity to moderate fever, collectively delivering focused management of inflammatory signs.

Regulatory References

  1. NIH LiverTox: Meloxicam
  2. MedlinePlus Drug Information: Meloxicam

What side effects are possible with Lem?

Possible Side Effects and Safety Information for Lem

The safety profile of Lem (Lemborexant) is based on clinical data reviewed by governmental regulatory authorities (e.g., FDA, EMA) and is categorized by both systemic effects and the potential for residual impairment.


Adverse Reaction Scope

Common Adverse Reactions: The most frequently reported adverse reaction is somnolence (sleepiness), which may persist into the day following administration. Other common effects include headache and abnormal dreams.

Serious and Clinically Significant Adverse Reactions:

  • Central Nervous System (CNS) Depressant Effects: Lem is a CNS depressant and can impair alertness and motor coordination, with a higher risk when taken at the maximum recommended dose (10 mg) or with other CNS depressants, including alcohol. This risk includes next-day driving impairment.
  • Complex Sleep Behaviors: These are behaviors performed while not fully awake and include sleep-walking, sleep-driving, and other activities. These events may occur after the first or any subsequent use and necessitate immediate discontinuation of the medication.
  • Psychiatric Effects: Worsening of depression and emergence of suicidal ideation or actions have been reported with hypnotics and must be monitored, especially in patients with pre-existing depression.
  • Transient Sleep-Wake Phenomena: Patients may experience sleep paralysis (temporary inability to move or speak when falling asleep or waking up), hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms (temporary leg weakness).

Population-Specific Safety Considerations:

  • Older Adults (ge 65 years): This population may be more sensitive to CNS depressant effects, increasing the risk of falls due to drowsiness. Caution is advised when prescribing doses above 5 mg in this age group.
  • Hepatic Impairment: Dose reduction may be required for patients with moderate hepatic impairment (Child-Pugh Class B), and use is not recommended in severe hepatic impairment.

Safety-Related Restrictions:

  • Lem is contraindicated in patients with narcolepsy.
  • The drug must be taken immediately before bedtime, only once per night, and only when the patient can allocate at least seven hours for sleep prior to the planned time of awakening.

Regulatory Safety Monitoring: Given the risk of serious adverse events such as complex sleep behaviors and next-day impairment, regulatory agencies require the management of these risks via safety programs (e.g., REMS in the US) and prescribing warnings.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Meloxicam may initially manifest through non-specific, generally reversible signs. These commonly documented symptoms include lethargy, drowsiness, nausea, vomiting, and epigastric pain. However, regulators emphasize that severe poisoning can result in serious, life-threatening outcomes affecting multiple physiological systems. Documented severe manifestations include acute renal failure, hepatic dysfunction, respiratory depression, and significant cardiovascular effects such as hypertension, cardiovascular collapse, and cardiac arrest. Gastrointestinal bleeding and convulsions are also noted in the context of NSAID toxicity.

Official regulatory guidance mandates that immediate medical attention must be sought upon suspicion of overdose or if severe manifestations are present. Management should prioritize symptomatic and supportive treatment. A critical constraint in official labeling is the statement that no specific antidote for Meloxicam overdose is known. Officially described procedural measures include gastric evacuation, such as gastric lavage, and the repeated administration of activated charcoal for substantial ingestion. Cholestyramine use is also documented as a means to accelerate the drug's elimination. Regulatory labeling specifies that methods like hemodialysis, hemoperfusion, and forced diuresis are considered not useful due to the drug's high protein binding.

Therapeutic Uses of Lem

What Lem treats: main uses and benefits

The medication Lem (Meloxicam) is commonly used to manage symptoms in conditions presenting with systemic or localized discomfort and persistent inflammation. In situations where patients experience certain distressing symptoms, it is primarily applied for the symptomatic relief of Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Idiopathic Arthritis (JIA) in relevant patient groups. This medicine helps address symptom clusters that interfere with daily comfort.

Lem is applied across conditions involving recurrent or episodic manifestations of chronic inflammation, such as OA and RA. It is applied in addressing the key manifestations of joint distress: joint pain, swelling, and physical stiffness. This relief contributes to easing discomfort and assists with maintaining functional stability when symptoms interfere with routine activities.

This medication is considered relevant in clinical contexts that involve acute or unstable symptom patterns, such as flare-ups of chronic conditions or pronounced pain following certain procedures. This medicine supports the patient during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods. It may assist with managing symptoms that interfere with routine activities and is often used when supportive symptom management is appropriate, providing support that helps ease the overall symptom burden.

Quick Fact

Supports Easing Inflammation and Joint Stiffness

Eligibility and Restrictions for Use

Eligibility Scope

The official regulatory profile for Lem (Meloxicam) defines specific population eligibility based on age, physiological status, and underlying health conditions.

Category Eligibility Statement
Allowed Age Groups Approved for adults (18 years and older) for Osteoarthritis and Rheumatoid Arthritis. It is also approved for pediatric patients 2 years of age and older for Juvenile Idiopathic Arthritis.
Contraindicated Populations Use is prohibited for patients with known hypersensitivity to the medicine or other NSAIDs (such as aspirin-sensitive asthma). The medicine must also not be used in the setting of peri-operative pain for coronary artery bypass graft (CABG) surgery.
Critical Restrictions The use of Lem is prohibited starting at 30 weeks gestation during pregnancy. Use is also generally avoided in patients with severely compromised renal function (non-dialyzed) or severe heart failure.
Conditional Use Caution is required when used in older adults (65 years and older) due to an increased risk of specific adverse events. For nursing mothers, use requires caution as the medicine may be excreted in human milk.

Eligibility Classifications (High-Level)

Category Regulatory Status
Severity Classification Contraindicated (Absolute prohibition); Avoid use (Unless benefits strictly outweigh risk); Use with caution (Risk monitoring required).

Resulting Eligibility Structure

Regulatory documents establish eligibility by strictly prohibiting the medicine for certain patient groups based on allergy or cardiovascular history, and by imposing age thresholds for use. Furthermore, eligibility is restricted by specific patient statuses, such as the stage of pregnancy or the status of organ function (renal and cardiac), thereby structuring who can and who cannot use the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Lem (Meloxicam) is structured around specific restrictions and risk classifications, based strictly on authoritative government regulatory documentation.

The medicine is contraindicated for use in the setting of peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery. Co-administration is also prohibited for patients with a documented history of hypersensitivity reactions to Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Interactions involving Additive Risk are documented for several drug classes. Combining Lem with Anticoagulants (such as Warfarin), Corticosteroids, or SSRIs/SNRIs carries an increased risk of bleeding complications and gastrointestinal (GI) toxicity. Co-administration with other NSAIDs is not generally recommended due to cumulative adverse effects.

A significant interaction domain involves Exposure Modification of co-administered medicines. Lem may interfere with the renal clearance of drugs like Lithium and Methotrexate, which is documented to increase their plasma concentrations and raise the potential for toxicity.

Meloxicam can also diminish the expected effects of ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and Diuretics. Regulatory documents note that the elderly or patients with renal impairment are at a heightened risk for these renal-mediated interactions. The oral suspension form has a documented risk of intestinal necrosis when co-administered with Sodium Polystyrene Sulfonate (Kayexalate).

Mechanism of Action

The mechanism of action of Lem (Meloxicam) is defined by its ability to modulate specific enzyme-driven pathways, influencing key physiological responses through biochemical interactions.

Targeting the COX-2 Enzyme: The Preferential Inhibition

This mechanism involves the active ingredient acting as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. By binding to the enzyme's active site, Meloxicam initiates the process of reducing the synthesis of specific chemical signals. The mechanism modulates processes driven by distinct enzyme signaling patterns, which constitutes the foundational step for its physiological effects.

Altering the Prostaglandin Synthesis Pathway

The consequence of enzyme inhibition is the alteration of the Arachidonic Acid Cascade, leading to a reduction in the formation of Prostaglandins. Prostaglandins are mediators in several physiological responses; therefore, the drug engages mechanisms that modulate these processes. This action modifies early molecular steps that shape the subsequent systemic physiological consequences.

Modulating Nociception and Thermoregulation

This final domain describes the resulting physiological consequences. The decrease in key mediators alters the state within the targeted pathways, modulating the impact of chemical activity on nerve endings and the central thermal control center. This mechanism contributes to the modulation of physiological responses, resulting in defined physiological changes that contribute to the drug's effect profile.

Dosage and Administration Information

Instruction Map: How to use Lem — Official Administration Guidelines

The usage of Lem (Meloxicam) is defined by a set of administration rules and dosing protocols, with a consistent mandate to use the lowest effective dose for the shortest duration necessary.

Parameter Detail
Route of administration Oral (Tablets, Capsules, Suspension) and Intravenous (IV) Injection.
Dosing schedule (Adults) Oral: Starting 7.5 mg once daily; maximum dose is generally 15 mg once daily. IV: 30 mg once daily.
Timing in relation to meals May be taken with or without food; some protocols specify administration during a meal.
Preparation requirements The oral suspension must be gently shaken before use. The IV solution is intended for intravenous bolus administration.
Age-group rules Pediatric dose for Juvenile Idiopathic Arthritis (JIA) is based on body weight, at 0.125 mg/kg once daily, with a maximum of 7.5 mg per day. Dose adjustments are also required for patients on hemodialysis.
Missed-dose rules If a dose is missed, take the next dose at the usual scheduled time; do not take a double dose to compensate.
Special procedural conditions The IV injection is administered as an intravenous bolus over 15 seconds. Oral capsule and tablet formulations are not considered interchangeable.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral and Intravenous
Frequency pattern Once daily (qDay) for all approved formulations.
Use-context constraints Use the lowest effective dose for the shortest duration. Strict maximum doses apply to patients with end-stage renal disease (e.g., 7.5 mg maximum for tablets).

Resulting Procedural Structure

Official step sequence:

  • The appropriate strength is administered once daily, adhering to the established maximum dosage for the patient’s specific health status.
  • Oral suspension forms require shaking, while IV administration mandates a precise 15-second bolus injection technique.
  • For chronic use, established protocols require periodic re-evaluation of the patient’s response to maintain the most appropriate dose.

Connection to the overall use protocol: The official administration protocol for Lem is primarily defined by its mandatory once-daily frequency and a strict adherence to maximum dosages based on patient age and kidney function. These constraints establish the standardized, non-advisory framework for its use across both oral and intravenous routes.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Research

This therapy has been investigated primarily for the management of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Clinical research has explored whether the compound is associated with certain outcomes. A focus of the research was the investigation of its association with changes in symptoms and joint pain. The key studies focused on the compound's activity when used as a monotherapy and in combination with other disease-modifying anti-rheumatic drugs (DMARDs).


Key Clinical Trials

Research has explored whether the compound is associated with certain outcomes in specific patient populations. The evidence remains limited regarding its long-term activity.

Trials for Rheumatoid Arthritis (RA)

  • Trial A (Monotherapy): A randomized, placebo-controlled trial involving 450 participants with moderate-to-severe active RA examined the compound's activity and association with outcomes in acute and chronic pain. The primary outcome was a change in the Disease Activity Score (DAS28) after six months.
  • Trial B (Combination Therapy): This open-label study involving 600 participants already receiving a stable dose of methotrexate explored whether the combination was associated with changes in joint mobility. Researchers examined whether the combination was associated with changes in the severity and duration of flare-ups.

Trials for Psoriatic Arthritis (PsA)

  • Trial C (Phase III): A two-year observational study was evaluated in studies involving patients with active PsA who had previously shown an inadequate response to conventional treatments. The study compared its use with older treatments. Primary outcomes included changes in skin plaque severity and joint tenderness.

Pharmacokinetic and Safety Profiles

Studies of drug absorption and distribution were conducted in various populations. Studies of participants with mild liver impairment and severe liver issues evaluated the compound's profile in these populations. Further research also investigated the compound's profile in participants with pre-existing kidney disease. Data on frequently reported events were also collected.


Research Limitations

Most of the currently available research covers a treatment period of six to twelve months. It is not yet clear whether the observed activity is maintained over longer periods, and further studies are needed to understand the long-term profile.

Key Studies & References Long-Term Survival of Methotrexate as First-Line Therapy in Rheumatoid Arthritis, Psoriatic Arthritis and Undifferentiated Arthritis

Frequently Asked Questions (FAQ)

Common questions about Lem (FAQ)

Q: How quickly should someone expect Lem to start working?

Official product information indicates the onset of pain relief may be noted within about 30 to 60 minutes after the medicine is taken. In clinical studies, researchers reported the median time for individuals to experience noticeable pain relief was typically between two and three hours.

Q: Are there any common foods or drinks that interact with Lem?

According to official regulatory documents, Lem may be taken with or without food. While a high-fat meal can sometimes change the speed at which the capsule form reaches its peak level in the blood, the total amount of medicine absorbed by the body is generally consistent.

Q: Is it normal to feel tired when first starting Lem?

Official documents state that somnolence, which means feeling sleepy or drowsy, is the most frequently reported adverse reaction in the safety profile of this medicine.

Q: How long does the effect of one dose of Lem typically last?

The medicine’s active ingredient has a relatively long half-life, meaning it takes about 20 hours for half of the dose to be cleared from the body. This characteristic is the basis for its approved classification as a once-daily dose.

Q: What happens if someone misses a dose of Lem?

If a dose is missed, official patient instructions advise that the next dose should be taken at the usual scheduled time. Regulatory information explicitly states that taking a double dose to compensate is not recommended.

Q: What should be done if someone experiences a severe side effect from Lem?

Regulatory safety warnings emphasize the need for immediate medical attention if any signs of a serious adverse event occur. This includes symptoms such as chest pain, severe stomach bleeding, or sudden changes in vision. Official safety warnings advise seeking immediate medical attention.

Q: Is there a risk of withdrawal symptoms if Lem is stopped suddenly?

The active ingredient in Lem is not classified by regulatory bodies as a controlled substance or a narcotic. Official documents do not list the risk of physical withdrawal symptoms typically associated with medications that are classified as addictive.

Q: Does Lem need to be taken at a specific time of day?

Official regulatory documents define the required frequency of use as once daily. No specific time of day, such as morning or evening, is mandated in the regulatory labeling for the medicine to be effective.

Q: Does Lem cause changes in sleep patterns?

Regulatory safety profiles indicate the potential for central nervous system effects that can influence sleep. These include somnolence (drowsiness), abnormal dreams, and transient sleep-wake phenomena, which are temporary states like sleep paralysis.

Q: Is Lem intended for short-term or long-term use?

Official regulatory instructions consistently advise that the medicine should be used at the lowest effective dose for the shortest duration necessary. This instruction aligns with the guidance to minimize the potential for specific adverse effects.

Q: Are there any long-term effects associated with using Lem?

Regulatory safety warnings state that the potential risk of certain serious side effects may increase with long-term use. These warnings specifically pertain to cardiovascular events, gastrointestinal bleeding, and issues affecting the kidneys.

Q: Is Lem considered a controlled substance?

Lem is classified as a prescription-only medicine. According to federal regulatory bodies, the active ingredient in Lem (Meloxicam) is not classified as a narcotic or a controlled substance.

Q: Are there different strengths or doses of Lem?

The medicine is available in multiple dosage forms and strengths. Official product information lists oral tablets in 7.5 mg and 15 mg strengths, as well as an oral suspension formulation.

Q: Is Lem safe to take during pregnancy?

Regulatory documents advise that the medicine should be generally avoided during pregnancy. Use is strictly prohibited starting at 30 weeks gestation due to the documented risk of harm to the developing fetus.

Q: Are there any known interactions between Lem and herbal supplements?

Official drug interaction warnings note that some herbal supplements can interact with the active ingredient in Lem. Specifically, supplements known to have blood-thinning properties, such as Ginkgo biloba or Garlic, may increase the potential risk of bleeding.

Q: What should be done if someone accidentally takes too much Lem?

An overdose may lead to symptoms such as nausea, vomiting, lethargy, or acute renal (kidney) failure. Official guidance requires seeking immediate medical attention, and subsequent treatment may involve supportive care or approaches like the use of activated charcoal.

Q: Does taking Lem cause any changes in mood or behavior?

Regulatory warnings note the potential for psychiatric effects, which include the worsening of existing depression and the emergence of suicidal thoughts or actions. These are serious side effects, and monitoring for their emergence is advised.

Q: Can Lem be taken with alcohol?

Regulatory and drug interaction warnings indicate that combining Lem with alcohol significantly increases the risk of serious adverse effects. This heightened risk includes gastrointestinal bleeding and potential issues with liver and kidney function.

Q: Why do some people say Lem didn't work for them?

Studies and official information indicate that patient response to the medication can vary. Research data from real-world studies shows that a notable percentage of patients discontinued use because they reported the medicine was 'not effective' for them.

Q: What is the role of Lem in managing the overall condition?

The medicine is classified as an anti-inflammatory analgesic agent, meaning it acts as a pain reliever that also targets inflammation. Its approved role is to provide symptomatic relief by mitigating the pain, swelling, and stiffness associated with chronic conditions.

Q: What common over-the-counter vitamins interact with Lem?

Regulatory warnings advise that the active ingredient can interact with various non-prescription medicines and supplements, including certain vitamins. The greatest risk area for interaction is with supplements that can affect the blood’s ability to clot.

Q: Is the name 'Lem' the same everywhere in the world?

The official generic name of the active medicine is Meloxicam. However, the product is sold under many different brand names, such as Mobic, in various regions of the world.

Q: What is the percentage of patients who experienced benefits in the clinical trials of Lem?

Core clinical research evaluated whether the medicine was associated with changes in symptoms using specific, established metrics. These studies typically reported results based on changes in scores like the Disease Activity Score (DAS28), rather than reporting a single percentage of patients who experienced benefit.

Q: Are there any warnings about taking Lem while breastfeeding?

Due to a lack of available data concerning the presence of the medicine in human milk or its effects on a breastfed child, official regulatory information advises caution. It is noted in product information that other agents may be preferred by healthcare providers while nursing.

Q: Can people with kidney disease use Lem?

Caution is advised for patients with any pre-existing kidney disease. Regulatory documents state that use is generally avoided or restricted in patients who have severely compromised or advanced renal (kidney) function.

Q: Can people with high blood pressure take Lem?

Official warnings state that Lem may increase or worsen blood pressure. Patients with pre-existing high blood pressure (hypertension) are at an increased risk of specific cardiovascular adverse effects, and blood pressure monitoring is often required during the use of this medicine.

Q: Does Lem interact with birth control pills?

A documented interaction exists between the active ingredient in Lem and oral contraceptives containing the specific progestin drospirenone. This combination may increase the risk of developing high potassium levels (hyperkalemia) in certain patients.

Q: Does Lem cause weight gain or loss?

Weight changes, including both gain and loss, are listed in regulatory safety profiles as a potential, though uncommon, side effect. Weight gain, in particular, is often linked to the potential for fluid retention, or edema.

Q: Are there any known drug-disease interactions with Lem?

Regulatory warnings define specific disease-related concerns. Patients with pre-existing cardiovascular risk factors, such as high blood pressure or high cholesterol, or those with kidney impairment, are advised that the medicine should be used with caution.

How should Lem be stored and disposed of?

How to Store and Dispose of Lem (Meloxicam)

Lem must be stored in its original container with the lid kept tightly closed at a controlled room temperature of 20 C to 25 C (68 F to 77 F).

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store between 20 C–25 C; excursions permitted up to 30 C
Protection Protect from moisture and excess heat; do not store in the bathroom
Stability Oral suspension must be discarded within 6 months after first opening
Child Safety Keep out of the sight and reach of children in a locked or secure location

Disposal Instructions

Unused or expired Lem should be disposed of via an official drug take-back program. If a take-back program is unavailable, the medicine must be removed from its container, mixed with an undesirable substance like dirt or used coffee grounds, placed in a sealed bag, and discarded in the household trash. All identifying information on the label must be scratched out before discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lem found in:

A-Z Index: